Pharmaxis Ltd reported earnings results for the first quarter ended September 30, 2022. For the first quarter, the company reported revenue was AUD 8.08 million compared to AUD 5.89 million a year ago. Net income was AUD 0.943 million compared to net loss of AUD 3.03 million a year ago.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.023 AUD | +4.55% | +21.05% | +15.00% |
04-30 | Transcript : Syntara Limited, Q3 2024 Earnings Call, Apr 30, 2024 | |
04-10 | Syntara Reaches 50% Recruitment in Phase 2 Trial for Bone Marrow Cancer Treatment | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+15.00% | 17.55M | |
+42.83% | 748B | |
+34.11% | 598B | |
-5.70% | 356B | |
+18.06% | 325B | |
+4.63% | 283B | |
+17.02% | 245B | |
+9.26% | 211B | |
-4.21% | 209B | |
+2.43% | 166B |
- Stock Market
- Equities
- SNT Stock
- News Syntara Limited
- Pharmaxis Ltd Reports Earnings Results for the First Quarter Ended September 30, 2022